Peripherin and periaxin, biomarkers of peripheral axonal damage and demyelination, respectively, have recently been validated in Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The gene discussed is PRPH; the disease is Guillain-Barre syndrome.